Ivax Generic Paclitaxel Clears FDA; Bristol Patent Case Pending In N.Y.
Executive Summary
FDA has approved Ivax' generic version of the anticancer agent paclitaxel despite Bristol-Myers Squibb's announced relisting of a recently issued patent in the "Orange Book."
You may also be interested in...
Cancer “Moonshot” Launch Team Announced: Uncomfortable Ties To Anti-Industry Headlines
The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.
Ivax paclitaxel
First generic version of Bristol's Taxol will begin shipping within three weeks, Ivax said Sept. 20. Ivax will have 180 days of exclusivity following the launch of 30 mg/5 mL, 150 mg/25 mL and 300 mg/50 mL multiple-dose vials. Ivax made the announcement following the tentative approval of Mylan's 30 mg/5 mL paclitaxel ANDA. Ivax' ANDA was approved Sept. 15 (1"The Pink Sheet" Sept. 18, p. 3)
Ivax paclitaxel
First generic version of Bristol's Taxol will begin shipping within three weeks, Ivax said Sept. 20. Ivax will have 180 days of exclusivity following the launch of 30 mg/5 mL, 150 mg/25 mL and 300 mg/50 mL multiple-dose vials. Ivax made the announcement following the tentative approval of Mylan's 30 mg/5 mL paclitaxel ANDA. Ivax' ANDA was approved Sept. 15 (1"The Pink Sheet" Sept. 18, p. 3)